Fractyl Highlights GLP-1 Gene Therapy Potential, Delays Clinical Trials to 2025

1. Fractyl's GLP-1 Gene Therapy Pitch: Fractyl Health pitched the potential of its GLP-1 gene therapy at the ADA24 conference, highlighting its potential benefits for diabetes treatment.
2. Clinical Trials Delayed: Despite the promising pitch, Fractyl has pushed back the start of clinical trials for diabetes from 2024 to 2025.
3. Weight Maintenance Pipeline Advancement: Fractyl announced the acceleration of its Revita weight maintenance clinical study, REMAIN-1, with open-label data from the REVEAL-1 cohort expected in Q4 2024.